Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Gilead Sciences, Inc. — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.66, while Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while YieldMax AMD Option Income Strategy ETF pays none. Which is the better fit depends on your goals.
| AMDY | GILD | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $155.80 |
52-Week Low | $29.80 | $110.56 |
Market Cap | — | $168.35B |
Enterprise Value | — | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.90, up 3.01% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, including $0.68 on August 5, 2026, but key valuation ratios like P/E and P/S are unavailable. Recent news highlights high yield potential but cautions on net asset value erosion amid AMD stock volatility.
Outlook hinges on AMD's performance; the ETF offers income via call spreads but faces NAV decline risks if AMD rallies sharply. Investors should weigh high distributions against potential capital depreciation, with sentiment mixed among analysts citing sustainability concerns.
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
